OMERS ADMINISTRATION Corp Makes New $644,000 Investment in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

OMERS ADMINISTRATION Corp bought a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 41,900 shares of the company's stock, valued at approximately $644,000. OMERS ADMINISTRATION Corp owned approximately 0.15% of ClearPoint Neuro at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Millennium Management LLC raised its holdings in shares of ClearPoint Neuro by 5.0% in the 4th quarter. Millennium Management LLC now owns 289,150 shares of the company's stock worth $4,447,000 after purchasing an additional 13,866 shares in the last quarter. Lazard Asset Management LLC increased its position in shares of ClearPoint Neuro by 69.0% in the fourth quarter. Lazard Asset Management LLC now owns 23,106 shares of the company's stock worth $355,000 after acquiring an additional 9,433 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of ClearPoint Neuro in the fourth quarter worth approximately $265,000. D. E. Shaw & Co. Inc. increased its position in shares of ClearPoint Neuro by 27.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 288,409 shares of the company's stock worth $4,436,000 after acquiring an additional 62,889 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in shares of ClearPoint Neuro by 23.2% in the fourth quarter. Cubist Systematic Strategies LLC now owns 65,591 shares of the company's stock worth $1,009,000 after acquiring an additional 12,372 shares in the last quarter. 30.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on CLPT shares. Wall Street Zen downgraded shares of ClearPoint Neuro from a "hold" rating to a "sell" rating in a research report on Thursday. Stifel Nicolaus lifted their target price on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Finally, B. Riley increased their price objective on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th.

ClearPoint Neuro Price Performance

CLPT traded down $0.19 on Friday, reaching $11.89. 172,203 shares of the company traded hands, compared to its average volume of 236,071. The stock's 50 day moving average price is $12.80 and its 200-day moving average price is $14.21. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $19.22. The company has a market cap of $332.79 million, a price-to-earnings ratio of -17.23 and a beta of 1.03.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The company had revenue of $8.49 million for the quarter, compared to analysts' expectations of $8.21 million. As a group, equities research analysts forecast that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.